Flare Therapeutics: Funding, Investors & Team (Oct 2026)
Flare Therapeutics is a biotech firm that is venturing into a new therapeutic domain by taking a unique approach to decode the biology of transcription factors, in order to develop remedies in the form of small molecule medications. The team at Flare has discovered certain areas known as 'switch sites', which can be targeted for governing transcription factors and correcting mutation-induced ailments. Through its drug discovery program, which primarily centers around precision oncology, Flare has made significant progress in developing a drug pipeline aimed at tackling well-established transcription factors, and is looking to expand into fields such as neurology, immunology and inflammation, as well as rare genetic disorders.
Flare Therapeutics has raised $208M across 2 funding rounds on record, the most recent a Series C of $85.0M announced in Jun 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Flare Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Flare Therapeutics Funding Rounds
Flare Therapeutics raised $123M in a Series B announced in Mar 2023.
3.3 years later, a Series C of $85.0M was announced in Jun 2026.
Flare Therapeutics Founders and Leadership Team
Contact details for the Flare Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Flare Therapeutics Funding Compared to Other Biotechnology Startups
Flare Therapeutics' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Flare Therapeutics in Biotechnology and Cambridge
Companies Similar to Flare Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Flare Therapeutics Funding FAQs
What does Flare Therapeutics do?
Flare Therapeutics is a biotech firm that is venturing into a new therapeutic domain by taking a unique approach to decode the biology of transcription factors, in order to develop remedies in the form of small molecule medications. The team at Flare has discovered certain areas known as 'switch sites', which can be targeted for governing transcription factors and correcting mutation-induced ailments. Through its drug discovery program, which primarily centers around precision oncology, Flare has made significant progress in developing a drug pipeline aimed at tackling well-established transcription factors, and is looking to expand into fields such as neurology, immunology and inflammation, as well as rare genetic disorders.
How much funding has Flare Therapeutics raised?
Flare Therapeutics has raised $208M across 2 rounds on record. The most recent is a Series C of $85.0M announced in Jun 2026.
When did Flare Therapeutics last raise funding?
Flare Therapeutics' most recent funding round on record is a Series C of $85.0M, announced in Jun 2026.
Who founded Flare Therapeutics?
FundedIQ lists Doug Manion (Founder) at Flare Therapeutics.
Who is the CEO of Flare Therapeutics?
Amit Rakhit is listed as CEO at Flare Therapeutics.
Where is Flare Therapeutics headquartered?
Flare Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Flare Therapeutics have?
Flare Therapeutics is in the 11-50 employee band.
How does Flare Therapeutics' funding compare to other Biotechnology startups?
Flare Therapeutics' latest round of $85.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Flare Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Flare Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.